March 18, 2021 -- Cytovia Therapeutics has signed two agreements for research and development and manufacturing operations to move the company's chimeric antigen receptor (CAR)-natural killer (NK) cells derived from universal induced pluripotent stem cells (iPSCs) toward clinical trials in the fourth quarter of 2021 and its gene edited iPSC CAR-NK cells by 2022.
Under the first agreement with the Accelerator and Bioincubator Lab (ABI-LAB), Cytovia will move into a laboratory space at the ABI-LAB facility in Natick, MA. The company has started recruiting research and development and process development personnel to its team. Cytovia will maintain its existing cell therapy operation with the New York Stem Cell Foundation and antibody good manufacturing practice (GMP) manufacturing with STC Biologics.
The Natick labs will conduct activities for NK cell biology, gene editing, antibody and CAR development, and NK cell pilot manufacturing. The NK cell technology will be directly transferred to larger-scale operations in Puerto Rico.
Under the second agreement, Cytovia has signed a long-term joint manufacturing and operations agreement with BioSciencesCorp in Puerto Rico. This will integrate Cytovia's manufacturing processes within an existing 95,000-sq-ft current GMP (cGMP) facility that includes more than 40,000 sq ft of clean-room and biomanufacturing space. The facility is located in Aguadilla, Puerto Rico. Cytovia will recruit manufacturing personnel beginning in summer 2021.